Sompraz%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520hp

The provided drug name "Sompraz%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520hp" appears to be corrupted or incomplete. Assuming this refers to **esomeprazole**, the following information is provided. ## Overview Esomeprazole is a proton pump inhibitor (PPI) that reduces gastric acid production. ## Primary Indications * Gastroesophageal reflux disease (GERD) - healing of erosive esophagitis and maintenance of healing, symptom relief. * Treatment of duodenal ulcers. * Eradication of *Helicobacter pylori* infection (in combination with antibiotics). * Prevention of NSAID-associated gastric ulcers in patients at risk. * Pathological hypersecretory conditions, including Zollinger-Ellison syndrome. ## Adult Dosing * **GERD (healing erosive esophagitis):** 20 mg or 40 mg once daily for 4-8 weeks. * **GERD (maintenance of healing):** 20 mg once daily. * **GERD (symptom relief):** 20 mg once daily. * **Duodenal Ulcers:** 20 mg once daily for 4 weeks. * ***H. pylori* eradication:** 20 mg twice daily for 10 days in combination with amoxicillin and clarithromycin. * **Prevention of NSAID-associated gastric ulcers:** 20 mg once daily. * **Pathological hypersecretory conditions:** Starting dose typically 40 mg twice daily. Maximum dose is 40 mg twice daily, but higher doses may be used if indicated, up to 240 mg daily in divided doses (unlabeled use). ## Pediatric Dosing Dosing varies significantly by indication and age/weight. Consult specific pediatric guidelines. * **GERD (ages 1-17):** * Healing erosive esophagitis: 10 mg once daily for 4 weeks (if weight < 20 kg) or 20 mg once daily for 4 weeks (if weight ≥ 20 kg). * Maintenance of healing/symptom relief: 10 mg once daily (if weight < 20 kg) or 20 mg once daily (if weight ≥ 20 kg). * **Treatment of *H. pylori* (ages 12-17):** 20 mg twice daily for 10 days with amoxicillin and clarithromycin. ## Dose Adjustments * **Hepatic Impairment:** * Severe hepatic impairment: Maximum dose is 20 mg once daily. * **Renal Impairment:** No dose adjustment necessary. ## Contraindications * Known hypersensitivity to esomeprazole, substituted benzimidazoles, or any component of the formulation. ## Adverse Effects Common: Headache, diarrhea, nausea, abdominal pain, constipation, flatulence, dry mouth. Less Common: Dizziness, insomnia, rash, pruritus. Serious: *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with long-term use, hypomagnesemia, vitamin B12 deficiency, fundic gland polyps. ## Key Drug Interactions * **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, vitamin B12. Reduced absorption. Separate administration. * **CYP2C19 substrates:** Clopidogrel (reduced antiplatelet effect). Consider alternative PPIs not extensively metabolized by CYP2C19 or monitor closely. * **CYP3A4 inducers/inhibitors:** May alter esomeprazole levels. * **Methotrexate:** May increase methotrexate levels. ## Monitoring * Monitor for signs and symptoms of *C. difficile* infection. * Consider monitoring serum magnesium levels, especially with prolonged therapy (≥1 year) or concurrent use of diuretics/digoxin. * Monitor for signs of bone fracture if indicated. * Monitor for B12 deficiency symptoms with prolonged use. ## Clinical Pearls * Administer at least 1 hour before meals. * Capsules and tablets can be opened and mixed with applesauce, yogurt, or juice for patients who have difficulty swallowing. Do not chew or crush. * Long-term PPI use is associated with increased risk of fractures, *C. difficile* infection, hypomagnesemia, and vitamin B12 deficiency. Use the lowest effective dose for the shortest duration necessary. * Esomeprazole is a CYP2C19 inhibitor and may affect the metabolism of other drugs. *** **Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant guidelines before making any clinical decisions. Drug information can change, and individual patient factors must always be considered.